Samsara Is Maintained at Buy by B of A Securities
Samsara Analyst Ratings
BofA Securities Maintains Samsara(IOT.US) With Buy Rating, Raises Target Price to $45
Samsara's Strong Growth and Market Execution Justify Buy Rating and Raised Price Objective
Morgan Stanley Maintains DexCom(DXCM.US) With Hold Rating, Cuts Target Price to $75
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $89
A Quick Look at Today's Ratings for DexCom(DXCM.US), With a Forecast Between $80 to $120
Barclays Keeps Their Hold Rating on Dexcom (DXCM)
Stifel Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $100
DexCom Analyst Ratings
Stifel Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $100
TD Cowen Maintains Samsara(IOT.US) With Buy Rating, Maintains Target Price $45
Samsara's Strong Market Position and Growth Trajectory Justify Buy Rating
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $130
RBC Capital Sticks to Their Buy Rating for Dexcom (DXCM)
Analysts' Opinions Are Mixed on These Technology Stocks: Varonis Systems (VRNS), Alkami Technology (ALKT) and Garmin (GRMN)
Lattice Semiconductor Analyst Ratings
Lattice Semiconductor in Spotlight as Raymond James Upgrades After Pullback
Dexcom (DXCM) Receives a Buy From Wells Fargo